by Press Office – King’s College London – neurosciencenews.com
Summary: Results of a phase three clinical trial of a novel brain cancer vaccine, DCVax-L, that uses a patient’s stem cells to target cancer cells extended survival by many months to years for glioblastoma patients.
A vaccine (DCVax-L), trialed at King’s College Hospital and other centers around the world, using patients’ immune cells to target brain cancer can extend survival by many months or, in some cases, years, the final unblinded results from a phase 3 clinical trial has shown.
The final results were published on Thursday, November 17 in JAMA Oncology.
This is the first time in 17 years that such significant outcomes have been achieved in a phase 3 trial for a systemic treatment in newly diagnosed glioblastoma, and the first time in 27 years that any treatment has been shown to extend survival in recurrent glioblastoma.